Transthyretin Amyloidosis with Cardiomyopathy
📧 Sign up to get email alerts when something new happens for Transthyretin Amyloidosis with Cardiomyopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-25Clinical Trial Update: CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) [Phase 3]
Phase 3 study of eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) has completed.
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]
A Phase 3 clinical trial evaluating vutrisiran for transthyretin amyloidosis with cardiomyopathy is currently enrolling by invitation.
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]
This clinical trial update reports on the Phase 3 HELIOS-B study evaluating vutrisiran for transthyretin amyloidosis with cardiomyopathy; re…
-
CLINICAL_TRIALS trial_result · 2023-10-18Clinical Trial Update: APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) [Phase 3]
APOLLO-B is a Phase 3 trial evaluating patisiran in transthyretin amyloidosis with cardiomyopathy. The study has completed, and results were…